Although the role of CD19+CD24+CD38+ and CD19+CD24+CD27+ regulatory B cells have been investigated in patients with type 1 autoimmune pancreatitis (Sumimoto et al., 2014), the specific mechanism of action of CD19 is yet to be determined in pancreatic cancer. This evidence concerns the gene CD24 and familial pancreatic carcinoma.